數位孿生模型在藥物研發的應用：策略性洞察與預測（2026-2031）

Digital Twin Models for Pharmaceutical R&D Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 155 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2026 年，醫藥研發領域數位孿生模型的市場規模將達到 6.108 億美元，到 2031 年將達到 12.535 億美元，2026 年至 2031 年的複合年成長率為 15.5%。

在藥物研發領域，數位孿生模型正經歷著重大變革，其驅動力包括：人工智慧驅動的藥物發現模式轉移、對提高研發效率日益成長的需求，以及監管機構對In Silico調查方法的日益重視。這一市場演變的特點在於，人們逐漸認知到，患者、生物系統、實驗室流程和設施的虛擬副本能夠預測治療結果、最大限度地減少臨床試驗失敗，並在整個藥物價值鏈中實現數據驅動的決策。人工智慧、機器學習、運算生物學和雲端運算的融合，使得數位孿生模擬更加快速、準確和全面。製藥公司正在採用這些技術，以應對傳統藥物研發中存在的成本高昂、研發週期長和失敗率高等問題。根據業界估計，一種新藥上市需要超過10年的時間，耗資超過26億美元。包括美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）在內的監管機構正在透過「良好人工智慧實踐」原則和「2028年藥品監管中的數據和人工智慧」工作計畫等框架，推動人工智慧和數位孿生技術的應用。市場正在大力投資人工智慧驅動的藥物發現平台、患者特異性數位孿生和臨床試驗模擬技術，其中數位孿生被視為未來藥物研發的基石。

市場促進因素

人工智慧、建模和模擬技術在製藥研發領域的日益普及是推動數位孿生模型市場發展的主要動力。絕大多數製藥公司都依賴這些技術來建立分子、患者、器官、生產系統和臨床試驗族群的數位孿生模型，使研究人員能夠在進行實際實驗之前建模數千種場景。製藥研發仍然是一項成本高昂且風險巨大的工作，根據業內估計，一種新藥的上市可能需要超過10年的時間，耗資超過26億美元。不斷成長的研發支出（預計到2026年，排名前50位的製藥公司研發支出將達到2,160億美元）正在推動先進建模技術的廣泛應用。根據IQVIA研究所發布的《全球研發趨勢》報告，預計未來五年每年將有70至80種新的活性成分上市，這將增加人工智慧驅動的數位孿生研發平台的壓力。藥物研發效率的日益提升推動了數位孿生模型的應用，該模型能夠在虛擬環境中模擬藥物行為和生物相互作用。透過利用人工智慧和機器學習，企業能夠及早發現潛在的失敗，改善化合物選擇，並顯著降低後期臨床試驗中高昂成本的失敗率。隨著個人化和精準醫療的日益普及，人們對能夠基於遺傳、環境和生活方式數據模擬個別治療反應的患者專屬數位孿生模型的需求也日益成長。生物系統和疾病的複雜性不斷增加，使得數位孿生模型必須能夠精確地模擬和重現人體生物功能隨時間的變化。數據分析和雲端運算基礎設施的進步正在革新海量生物和臨床數據的即時收集、處理和分析方式。

市場限制因素

高昂的實施和基礎設施成本是主要挑戰。開發和部署數位孿生模型需要對計算設施、數據管理系統和高素質人才進行大量投資。中小型製藥和生技公司往往難以承擔這些龐大的前期成本。高品質數據的匱乏限制了模型的有效性。不完整、有偏差或低品質的數據會導致預測結果不可靠，從而阻礙信任的建立和應用。網路安全和資料隱私問題是進一步的障礙。管理敏感的患者資訊和臨床記錄會增加資料外洩和網路攻擊的風險。嚴格的法律資料保護要求和隱私問題會使資料共用變得困難，可能限制數位孿生技術的應用。與現有IT系統和工作流程整合的複雜性也會對部署構成挑戰。

The digital twin models for pharmaceutical R&D market is undergoing significant transformation driven by the paradigm shift toward AI-enabled drug discovery, the growing need to improve R&D efficiency, and the increasing regulatory support for in silico methodologies. The market's evolution is characterized by the recognition that virtual replicas of patients, biological systems, laboratory processes, and facilities can predict treatment outcomes, minimize trial failures, and enable data-driven decision-making across the pharmaceutical value chain. The convergence of artificial intelligence, machine learning, computational biology, and cloud computing is enabling faster, more accurate, and increasingly comprehensive digital twin simulations. Pharmaceutical companies are adopting these technologies to address the high costs, lengthy timelines, and high failure rates associated with traditional drug development, with industry estimates indicating that taking a new drug to market takes more than 10 years and costs more than USD 2.6 billion. Regulatory agencies, including the U.S. FDA and the European Medicines Agency, are endorsing the use of AI and digital twin technologies through frameworks such as the "Good AI Practice" principles and the "Data and AI in Medicines Regulation to 2028" work plan. The market is witnessing significant investment in AI-enabled drug discovery platforms, patient-specific digital twins, and clinical trial simulation technologies, positioning digital twins as a cornerstone of future pharmaceutical R&D.

Market Drivers

The growing adoption of AI, modeling, and simulation technologies across pharmaceutical R&D represents the primary driver for the digital twin models market. The vast majority of pharmaceutical companies rely on these technologies to facilitate the development of digital twin models for molecules, patients, organs, manufacturing systems, and clinical trial populations, allowing researchers to simulate thousands of scenarios before conducting physical experiments. Pharmaceutical R&D continues to be a costly and high-risk endeavor, with industry estimates indicating that taking a new drug to market takes more than 10 years and costs more than USD 2.6 billion. Rising R&D expenditure, with top 50 pharmaceutical firms expected to spend USD 216 billion by 2026, supports broader adoption of advanced modeling technologies. The IQVIA Institute's Global R&D Trends report estimates that 70-80 novel active substances will be launched each year over the next five years, generating increased pressure on AI-driven and digital twin-enabled R&D platforms. The rising need to improve drug development efficiency is driving adoption of digital twin models that can simulate drug behavior and biological interactions in a virtual setting. Using AI and ML, enterprises can detect potential failures early, improve compound selection, and largely eliminate expensive late-stage clinical trial failures. The increasing focus on personalized and precision medicine is creating demand for patient-specific digital twins that simulate individual responses to treatments based on genetic, environmental, and lifestyle data. The growing complexity of biological systems and diseases is driving the need for digital twins that can model and replicate human biology accurately and over time. Advancements in data analytics and cloud computing infrastructure are revolutionizing the collection, processing, and analysis of huge amounts of biological and clinical data in real-time.

Market Restraints

High implementation and infrastructure costs present significant challenges. The development and implementation of digital twin models necessitate considerable investment in computing facilities, data management systems, and highly trained staff. Smaller pharmaceutical and biotechnology companies frequently face difficulties in financing these large initial expenses. Limited availability of high-quality data constrains model effectiveness. Incomplete, biased, or low-quality data can lead to unreliable predictions, which may hinder trust and adoption. Cybersecurity and data privacy concerns create additional barriers. Managing sensitive patient and clinical records makes potential data exposure and cyber-attack risks higher. Strong legal data protection requirements and privacy issues could make it difficult to share data and reduce the use of digital twin technologies. Integration complexity with existing IT systems and workflows can create implementation challenges.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of AI, machine learning, computational biology, and cloud-based platforms. AI accounts for the dominant market share, since it is used significantly in predictive modeling, biological simulations, and R&D optimization. Machine learning enables pattern recognition and predictive analytics from complex biological datasets. Computational biology supports mechanistic modeling of biological systems. IoT enables real-time data collection from laboratory and manufacturing environments. Big data analytics supports processing and interpretation of large-scale biological and clinical data. The segment analysis reveals that software platforms hold the largest share, owing to their heavy use for building, simulating, and overseeing digital twin models across pharmaceutical R&D. The patient twin segment was the leading segment in 2025, largely because of the rising focus on personalized medicine and more patient-centric development. Drug discovery and development is the dominant application segment, driven by the growing reliance on digital twins for target identification, molecular simulation, and candidate optimization. Clinical trial simulation is set to show significant growth fueled by the ongoing efforts to minimize the duration of preclinical and clinical phases, with digital twins providing a new alternative for reducing attrition and improving predictive efficacy. The integration of AI is becoming increasingly important because AI capabilities are faster in adoption, and influence is observed in areas including discovery research, clinical planning and operations, portfolio decision-making, and regulatory approvals.

Competitive and Strategic Outlook

The competitive landscape features established technology and software companies alongside specialized simulation, AI, and life sciences analytics providers. Siemens AG is a key player in the field of digital twin technology, with its complete digital enterprise portfolio and platforms such as Siemens Xcelerator supporting the development of detailed digital twins corresponding to physical assets, processes, and even whole production systems. Dassault Systemes is a major player in digital twin and simulation technologies, with its 3DEXPERIENCE platform creating virtual twins that allow pharma and biotech companies to digitally replicate biological systems, simulate different drug scenarios, and improve clinical trials as well as manufacturing. Microsoft Corporation is a key technology provider in the digital twin ecosystem, enabling pharmaceutical and life sciences companies to create connected, data-driven virtual representations through its Microsoft Azure ecosystem, combining cloud computing, AI, IoT, and advanced analytics. ANSYS provides simulation and modeling software for engineering and scientific applications. PTC offers digital twin solutions for product and process optimization. Companies are pursuing product portfolio expansion through innovation in AI-enabled platforms, patient-specific digital twins, and clinical trial simulation technologies. Strategic collaborations between technology providers, pharmaceutical companies, and research institutions are increasing, driven by the need for integrated digital twin solutions. Recent key developments include Certara launching version 25 of its biosimulation platform, the Simcyp Simulator, expanding digital-twin capabilities through integrated physiologically based pharmacokinetic modeling, virtual patient populations, and AI-enabled drug-development workflows. Dassault Systemes and NVIDIA have made public their strategic collaboration to create a joint industrial architecture for mission-critical AI applications, merging Dassault Systemes' Virtual Twin technologies and NVIDIA AI infrastructure. Microsoft was named a Leader in the 2025 Gartner Magic Quadrant for Global Industrial IoT Platforms. Siemens revealed several updates to its digital twin ecosystem featuring industrial AI capabilities, allowing continuous simulation, predictive analysis, and better management of a product's entire lifecycle.

Short Conclusion

The digital twin models for pharmaceutical R&D market is positioned for sustained growth driven by the convergence of AI adoption, R&D efficiency needs, and regulatory support. The transition from traditional experimental approaches toward integrated in silico platforms represents a fundamental shift in pharmaceutical development. While challenges related to high costs, data quality, and cybersecurity persist, strategic investments in technology, partnerships, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with digital twin models evolving into a cornerstone of pharmaceutical R&D, supporting drug discovery, clinical trial simulation, and personalized medicine across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

2. Market Snapshot

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. Business Landscape

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. Technological Outlook

4.1. Advances in AI-Driven Digital Twin Modeling Technologies
4.2. Multi-Scale and Mechanistic Modeling Innovation
4.3. Real-Time Data Analytics and IoT-Enabled Digital Twins
4.4. Generative AI and Foundation Models for Digital Twins

5. Future Outlook - Trends and Emerging Innovations

6. Digital Twin Models For Pharmaceutical R&D Market By Component (2021-2031)

6.1. Introduction
6.2. Software Platforms
6.3. Service

7. Digital Twin Models For Pharmaceutical R&D Market By Digital Twin Type (2021-2031)

7.1. Introduction
7.2. Patient Twin
7.3. Molecular Twin
7.4. Asset Twin
7.5. Product Twin
7.6. Others

8. Digital Twin Models For Pharmaceutical R&D Market By Technology (2021-2031)

8.1. Introduction
8.2. Artificial Intelligence
8.3. Machine Learning
8.4. Computational Biology
8.5. Internet of Things (IoT)
8.6. Big Data Analytics

9. Digital Twin Models For Pharmaceutical R&D Market By Application (2021-2031)

9.1. Introduction
9.2. Drug Discovery and Development
9.3. Clinical Trial Simulation
9.4. Personalized Medicine
9.5. Process Optimization and Manufacturing
9.6. Disease Modeling

10. Digital Twin Models For Pharmaceutical R&D Market By Geography (2021-2031)

10.1. Introduction
10.2. North America
- 10.2.1. USA
- 10.2.2. Canada
- 10.2.3. Mexico
10.3. South America
- 10.3.1. Brazil
- 10.3.2. Argentina
- 10.3.3. Others
10.4. Europe
- 10.4.1. United Kingdom
- 10.4.2. Germany
- 10.4.3. France
- 10.4.4. Spain
- 10.4.5. Others
10.5. Middle East and Africa
- 10.5.1. Saudi Arabia
- 10.5.2. UAE
- 10.5.3. Others
10.6. Asia Pacific
- 10.6.1. China
- 10.6.2. India
- 10.6.3. Japan
- 10.6.4. South Korea
- 10.6.5. Indonesia
- 10.6.6. Thailand
- 10.6.7. Others